Cells, Vol. 12, Pages 124: The SMARCD Family of SWI/SNF Accessory Proteins Is Involved in the Transcriptional Regulation of Androgen Receptor-Driven Genes and Plays a Role in Various Essential Processes of Prostate Cancer

Figure 1. Alterations of SMARCD1, SMARCD2 and SMARCD3 in two PCa patient cohorts. (A) SMARCD1, SMARCD2 and SMARCD3 were each found altered in 6% of patients (n = 488) suffering from non-metastatic prostate adenocarcinoma of various stages. While mutations were infrequent, the majority of alterations accounted for mRNA up-regulation. (B) In a cohort of patients with metastatic disease (n = 429), alterations of SMARCD1, SMARCD2 and SMARCD3 were detected in 5%, 11% and 9% of cases, respectively. The predominant types of alterations were mRNA up-regulation and gene amplifications.

Figure 1. Alterations of SMARCD1, SMARCD2 and SMARCD3 in two PCa patient cohorts. (A) SMARCD1, SMARCD2 and SMARCD3 were each found altered in 6% of patients (n = 488) suffering from non-metastatic prostate adenocarcinoma of various stages. While mutations were infrequent, the majority of alterations accounted for mRNA up-regulation. (B) In a cohort of patients with metastatic disease (n = 429), alterations of SMARCD1, SMARCD2 and SMARCD3 were detected in 5%, 11% and 9% of cases, respectively. The predominant types of alterations were mRNA up-regulation and gene amplifications.

Cells 12 00124 g001

Figure 2. mRNA and protein levels of SMARCD1, SMARCD2 and SMARCD3 in benign and malignant prostate cell lines. (A) Expression levels of SMARCD1, SMARCD2 and SMARCD3 in various prostate cell lines were measured by qPCR. RNA was isolated from several biological replicates (n = 3). Asterisks indicate the statistical significance of differences in gene expression between the respective cell line and non-malignant RWPE-1 cells. Error bars indicate the standard error of the mean (SEM). Standard deviations were calculated using the relative-fold expression determined in various technical replicates (n = 6). * p ≤ 0.05; ** p ≤ 0.01; **** p ≤ 0.0001. (B) SMARCD1, SMARCD2 and SMARCD3 protein levels in various prostate cell lines were determined by Western blotting.

Figure 2. mRNA and protein levels of SMARCD1, SMARCD2 and SMARCD3 in benign and malignant prostate cell lines. (A) Expression levels of SMARCD1, SMARCD2 and SMARCD3 in various prostate cell lines were measured by qPCR. RNA was isolated from several biological replicates (n = 3). Asterisks indicate the statistical significance of differences in gene expression between the respective cell line and non-malignant RWPE-1 cells. Error bars indicate the standard error of the mean (SEM). Standard deviations were calculated using the relative-fold expression determined in various technical replicates (n = 6). * p ≤ 0.05; ** p ≤ 0.01; **** p ≤ 0.0001. (B) SMARCD1, SMARCD2 and SMARCD3 protein levels in various prostate cell lines were determined by Western blotting.

Cells 12 00124 g002

Figure 3. SMARCD3 is an androgen-regulated gene. LnCAP cells were induced with various concentrations of DHT for (A) 8 h, (B) 24 h, (C) 48 h or (D) 72 h and SMARCD1, SMARCD2 and SMARCD3 expression levels were measured by qPCR. RNA was isolated from several biological replicates (n = 3). Asterisks indicate the statistical significance of differences in gene expression compared to the androgen-deprived control. Error bars indicate the standard error of the mean (SEM). Standard deviations were calculated using the relative-fold expression determined in various technical replicates (n = 6). * p 0.05; ** p 0.01; *** p ≤ 0.001; **** p ≤ 0.0001.

Figure 3. SMARCD3 is an androgen-regulated gene. LnCAP cells were induced with various concentrations of DHT for (A) 8 h, (B) 24 h, (C) 48 h or (D) 72 h and SMARCD1, SMARCD2 and SMARCD3 expression levels were measured by qPCR. RNA was isolated from several biological replicates (n = 3). Asterisks indicate the statistical significance of differences in gene expression compared to the androgen-deprived control. Error bars indicate the standard error of the mean (SEM). Standard deviations were calculated using the relative-fold expression determined in various technical replicates (n = 6). * p 0.05; ** p 0.01; *** p ≤ 0.001; **** p ≤ 0.0001.

Cells 12 00124 g003

Figure 4. Effects of siRNA-mediated silencing of SMARCD1, SMARCD2 and SMARCD3 in various combinations on cell viability. siRNA-mediated knockdown of SMARCD1, SMARCD2 and SMARCD3 alone or in various combinations was performed in the cell lines (A) LnCAP or (B) C4-2 and cell viability was determined after five days. If not indicated otherwise by brackets, asterisks indicate the statistical significance of differences in cell viability between the respective sample and the negative control. Error bars indicate the standard error of the mean (SEM). Standard deviations were calculated using the relative cell viability determined in various biological replicates (n = 7). * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001; ns: not significant.

Figure 4. Effects of siRNA-mediated silencing of SMARCD1, SMARCD2 and SMARCD3 in various combinations on cell viability. siRNA-mediated knockdown of SMARCD1, SMARCD2 and SMARCD3 alone or in various combinations was performed in the cell lines (A) LnCAP or (B) C4-2 and cell viability was determined after five days. If not indicated otherwise by brackets, asterisks indicate the statistical significance of differences in cell viability between the respective sample and the negative control. Error bars indicate the standard error of the mean (SEM). Standard deviations were calculated using the relative cell viability determined in various biological replicates (n = 7). * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001; ns: not significant.

Cells 12 00124 g004

Figure 5. Morphologic effects of siRNA-mediated knockdown of SMARCD1, SMARCD2 and SMARCD3 in LnCAP cells. Immunostaining of β–tubulin and nuclear pore complex (NPC) proteins was performed in LnCAP cells treated with (A) a scrambled control or siRNAs targeting (B) SMARCD1, (C) SMARCD2, (D) SMARCD3, (E) SMARCD1 and SMARCD2, (F) SMARCD1 and SMARCD3 and (G) SMARCD2 and SMARCD3. Arrows indicate binucleated cells.

Figure 5. Morphologic effects of siRNA-mediated knockdown of SMARCD1, SMARCD2 and SMARCD3 in LnCAP cells. Immunostaining of β–tubulin and nuclear pore complex (NPC) proteins was performed in LnCAP cells treated with (A) a scrambled control or siRNAs targeting (B) SMARCD1, (C) SMARCD2, (D) SMARCD3, (E) SMARCD1 and SMARCD2, (F) SMARCD1 and SMARCD3 and (G) SMARCD2 and SMARCD3. Arrows indicate binucleated cells.

Cells 12 00124 g005

Figure 6. Morphologic effects of siRNA-mediated knockdown of SMARCD1, SMARCD2 and SMARCD3 in RWPE-1 cells. Immunostaining of β–tubulin and nuclear pore complex (NPC) proteins was performed in RWPE-1 cells treated with (A) a scrambled control or siRNAs targeting (B) SMARCD1, (C) SMARCD2, (D) SMARCD3, (E) SMARCD1 and SMARCD2, (F) SMARCD1 and SMARCD3 and (G) SMARCD2 and SMARCD3. Arrows indicate binucleated cells.

Figure 6. Morphologic effects of siRNA-mediated knockdown of SMARCD1, SMARCD2 and SMARCD3 in RWPE-1 cells. Immunostaining of β–tubulin and nuclear pore complex (NPC) proteins was performed in RWPE-1 cells treated with (A) a scrambled control or siRNAs targeting (B) SMARCD1, (C) SMARCD2, (D) SMARCD3, (E) SMARCD1 and SMARCD2, (F) SMARCD1 and SMARCD3 and (G) SMARCD2 and SMARCD3. Arrows indicate binucleated cells.

Cells 12 00124 g006

Figure 7. Differentially regulated genes in response to siRNA-mediated silencing of the SMARCD genes and AR performed in the presence or absence of DHT. siRNA-mediated knockdown of (A) SMARCD1, (B) SMARCD2, (C) SMARCD3 and (D) AR was performed in LnCAP cells grown in the presence (left) or absence (center) of DHT. RNA-seq was performed using RNA isolated from several biological replicates (n = 3). Differential gene expression was considered statistically significant for genes with log2 fold changes > ± 1 and adjusted p-values < 0.05. Genes exhibiting differential regulation exclusively in the presence or absence of DHT or under both experimental conditions were assessed (right).

Figure 7. Differentially regulated genes in response to siRNA-mediated silencing of the SMARCD genes and AR performed in the presence or absence of DHT. siRNA-mediated knockdown of (A) SMARCD1, (B) SMARCD2, (C) SMARCD3 and (D) AR was performed in LnCAP cells grown in the presence (left) or absence (center) of DHT. RNA-seq was performed using RNA isolated from several biological replicates (n = 3). Differential gene expression was considered statistically significant for genes with log2 fold changes > ± 1 and adjusted p-values < 0.05. Genes exhibiting differential regulation exclusively in the presence or absence of DHT or under both experimental conditions were assessed (right).

Cells 12 00124 g007

Table 1. Origin and molecular feature of cell lines included in the study. The classical PCa cell line models LnCAP, C4-2, PC3 and DU145 and the non-malignant cell line RWPE-1 were included in the study. These cell lines represent various disease stages and differ in terms of androgen responsiveness and AR expression levels.

Table 1. Origin and molecular feature of cell lines included in the study. The classical PCa cell line models LnCAP, C4-2, PC3 and DU145 and the non-malignant cell line RWPE-1 were included in the study. These cell lines represent various disease stages and differ in terms of androgen responsiveness and AR expression levels.

Cell LineOriginAndrogen ResponsivenessAR ExpressionRWPE-1non-malignant epithelial prostate cells
immortalized with HPV18 [33]androgen responsive [33,34] high [34]LNCaPlymph node metastasis [35]androgen responsive [34,35]high [34]C4-2LnCAP subline isolated from
xenograft tumor of castrated mouse [36]androgen-independent [34,36] low [34]DU145brain metastasis [37]androgen-independent [34,37] none [34]PC3bone metastasis [38]androgen-independent
[34,38] none [34]

留言 (0)

沒有登入
gif